Allergy

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.

While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.

New data led to positive results for the simple-to-use PEN-FAST tool, allowing its use among allergists and even primary care physicians in cases in which access to allergists is limited.

This data indicates that public health officials may need to implement measures to both help prevent and detect domestic violence in order to reduce the associated effects.

Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.

Climate and vegetation changes in China may have led to increases in sensitivity to weed pollens and molds over the past 5 years, though the number one aeroallergen remains to be house dust mites.

Adaptation of penicillin allergy clinical decision tool PEN-FAST showed strong performance, indicating the potential utility of the tool for identifying patients with low-risk allergy phenotypes who may safely undergo direct oral challenges.

These findings are relevant given that if labels are incorrectly identified, those with allergies may be at risk of severe reactions or receive suboptimal treatment.

New research has led to the development of an algorithm designed to help improve detection of allergic reactions to antibiotics, given that antibiotics are among the most common medication adverse event causes.

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

There have been long stretches of time between the innovation of epinephrine delivery in the allergy space.

It was announced by ARS Pharmaceuticals, Inc., that a US Food and Drug Administration Drug Advisory Committee voted in favor of a new intranasal epinephrine treatment for severe allergic reactions.

Bryn Pharma is planning to submit the New Drug Application for Utuly this year and expects to receive approval early next year.

Data presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting show promise for Utuly, a novel intranasal epinephrine spray for treating anaphylaxis.

IgE-mediated children with cow’s milk allergies switching from amino acid-based formula to a new formula showed strong tolerance and better acquisition of immune tolerance, suggesting other studies combining treatments may be useful.

In this interview segment, Fleischer further described some of the key points about the peanut immunotherapy patch, DBV712, and the product’s phase 3 VITESSE trial.

In his interview, Fleischer discussed the beginning of a new phase 3 trial for a peanut immunotherapy patch known as DBV712.

New research into allergic disease examined changes over time as well as the characterization of remission versus continued disease.

New data expands upon the growing perception that allergenic food introduction early in a child’s life may lessen the possibility of allergy developments.

A novel allergen and immunotherapy adherence and persistence checklist was developed to allow for more insight into adherence and to open this information to prescribing clinicians.

This research letter highlighted the results of an allergy work-up and of vaccinations for COVID-19 in patients with a suspicion of mRNA vaccine hypersensitivity.

New data on peanut allergy and Pediatric Quality of Life Inventory scores sheds light on the burden of allergy on adolescents.

The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system. The treatment is being evaluated in patients with eosinophilic esophagitis and allergen sensitivity.

A research letter highlighted recent findings that iREACH educational intervention training may be helpful in preventing peanut allergies.

“These findings are exciting for us, and our overarching goal is to develop microbial biotherapeutics to treat food allergies," Mustafa Özçam says in an interview with HCPLive.

Practicing oral hygiene improves health issues from gum disease to cardiac disease, and Lebovic believes nasal hygiene can have that impact as well.

"The anticipation would be–wash your hands, brush your teeth, clean your nose–and allow that process to help the patients who suffer from allergy symptoms," lead investigator Dr. Arman Kalmakarian says.

In another interview segment, Castells discussed the safety profile of avapritinib for indolent systemic mastocytosis, as well as future research.

In another interview segment, Castells went further into depth regarding the PIONEER trial results and regarding avapritinib’s effect on mastocytosis.